Open and transparent ? Read our concerns over the WHO Expert Working Group process
Treating Too Few, Too Late Read about the case for starting ARV treatment earlier in developing countries click here
An ideal TB test ? Read interview with Access Campaign director
Job openings at the Campaign We are looking for a Medical Innovation Policy Adviser and an EU Policy Advocacy Assistant Read more
|
 |
|
 |
|
 |
The Campaign is promoting alternative ways of steering and funding medical research to meet the medical needs of people in developing countries, rather than market priorities.
The WHO Expert Working Group (EWG) on R&D financing is meeting in Geneva this week to conduct its initial review of various R&D financing proposals. MSF is concerned that there is a lack of transparency and basic information about the way the EWG is undertaking its work. Read more about our concerns 
|
Advance market commitments: what the doctor ordered? The scheme to boost access to a life-saving vaccine has finally got its formal kick-off. But what does the pneumococcal vaccine AMC mean? Is it all it's cracked up to be? Will it work? And what happens now?
|
|
|
Have a look at these animations explaining why people in developing countries can’t get the HIV medicines they need to survive and how setting up a ’patent pool’ could change that. MSF calls on researchers and pharmaceutical companies to act: put your patents in the pool! Click here |
|
Championing open source drugs: Leading geneticist Samir Brahmachari explains why India should kickstart a new 'open source' approach to drug discovery for diseases like TB. |
Major step forward WHO agrees on a plan to reform the medical R&D system and enhance access to medicines for patients in developing countries MSF statement Listen to the podcast on outcome of WHA and why it matters to our patients
|
Give us the tools we need...From an effective diagnostic test for TB, to drugs that work against Chagas disease and HIV treatments for children and pregnant women - none of these are available to our teams in the field because of the failure of the current system of medical R&D. Click here to read more about the medical challenges we face and some solutions that might deliver the medical tools we need to treat our patients. |
New Trials for Drug-Resistant TB
In a series of papers published by PLoS, international experts explain how innovative trials in patients with drug resistant TB could speed up delivery of new drugs, explore how to fill up the current TB pipeline with additional promising drugs and call for building of clinical trial capacity in developing countries. Paper on Randomized drug trials |
Introduction to Medical Innovation
Looking for alternative models
|
